Gastric cancer
E Van Cutsem, X Sagaert, B Topal, K Haustermans… - The Lancet, 2016 - thelancet.com
Gastric cancer is one of the leading causes of cancer-related death worldwide. Many
patients have inoperable disease at diagnosis or have recurrent disease after resection with …
patients have inoperable disease at diagnosis or have recurrent disease after resection with …
HER3 overexpression and survival in solid tumors: a meta-analysis
Background The human epidermal growth factor receptor 3 (HER3) is an ErbB/HER family
member that dimerizes with other ErbB receptors such as HER2. Numerous agents against …
member that dimerizes with other ErbB receptors such as HER2. Numerous agents against …
The pyroptosis-related signature predicts prognosis and indicates immune microenvironment infiltration in gastric cancer
W Shao, Z Yang, Y Fu, L Zheng, F Liu… - Frontiers in Cell and …, 2021 - frontiersin.org
Gastric cancer (GC) is one of the leading causes of cancer-related deaths and shows high
levels of heterogeneity. The development of a specific prognostic model is important if we …
levels of heterogeneity. The development of a specific prognostic model is important if we …
[PDF][PDF] HER2 in colorectal cancer: the long and winding road from negative predictive factor to positive actionable target
S Ahcene Djaballah, F Daniel, A Milani… - American Society of …, 2022 - researchgate.net
Human epidermal growth factor receptor 2 (HER2) is a well-known oncogenic driver in
different tumors and an approved therapeutic target in breast and gastroesophageal cancer …
different tumors and an approved therapeutic target in breast and gastroesophageal cancer …
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
E Van Cutsem, YJ Bang, F Feng-Yi, JM Xu, KW Lee… - Gastric cancer, 2015 - Springer
Abstract Background In the Trastuzumab for GAstric cancer (ToGA) study, trastuzumab plus
chemotherapy improved median overall survival by 2.7 months in patients with human …
chemotherapy improved median overall survival by 2.7 months in patients with human …
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial
E Van Cutsem, S de Haas, YK Kang, A Ohtsu… - Journal of clinical …, 2012 - ascopubs.org
Purpose The AVAGAST study showed that adding bevacizumab to chemotherapy in patients
with advanced gastric cancer improves progression-free survival and tumor response rate …
with advanced gastric cancer improves progression-free survival and tumor response rate …
[HTML][HTML] Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis
YY Janjigian, D Werner, C Pauligk, K Steinmetz… - Annals of oncology, 2012 - Elsevier
Background To determine whether human epidermal growth factor receptor 2 (HER2) status
is an independent prognostic factor in metastatic gastric and gastroesophageal junction …
is an independent prognostic factor in metastatic gastric and gastroesophageal junction …
DS‐8201a, a new HER2‐targeting antibody–drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2‐positive gastric cancer T‐DM1 …
N Takegawa, Y Nonagase, K Yonesaka… - … journal of cancer, 2017 - Wiley Online Library
Anti‐HER2 therapies are beneficial for patients with HER2‐positive breast or gastric cancer.
T‐DM1 is a HER2‐targeting antibody–drug conjugate (ADC) comprising the antibody …
T‐DM1 is a HER2‐targeting antibody–drug conjugate (ADC) comprising the antibody …
Heterogeneity in gastric cancer: from pure morphology to molecular classifications
Gastric cancer (GC) represents a global health concern. Despite advances in prevention,
diagnosis, and therapy, GC is still the third leading cause of cancer mortality worldwide, with …
diagnosis, and therapy, GC is still the third leading cause of cancer mortality worldwide, with …
Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer
M Terashima, K Kitada, A Ochiai… - Clinical Cancer …, 2012 - aacrjournals.org
Purpose: EGF receptor (EGFR) and HER2 positivity are considered to be negative
prognostic factors in gastric cancer. Biomarker analysis was conducted to evaluate the …
prognostic factors in gastric cancer. Biomarker analysis was conducted to evaluate the …